Cantor Fitzgerald Analysts Boost Earnings Estimates for PTCT

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for PTC Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will earn ($2.74) per share for the year, up from their previous forecast of ($3.26). Cantor Fitzgerald has a “Overweight” rating and a $113.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

A number of other equities research analysts also recently commented on the company. Royal Bank of Canada increased their price objective on PTC Therapeutics from $60.00 to $63.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Robert W. Baird increased their price objective on PTC Therapeutics from $52.00 to $70.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. Citigroup increased their price objective on PTC Therapeutics from $32.00 to $45.00 and gave the company a “sell” rating in a research report on Wednesday, February 12th. Wells Fargo & Company increased their price objective on PTC Therapeutics from $56.00 to $68.00 and gave the company an “overweight” rating in a research report on Tuesday, November 26th. Finally, Morgan Stanley upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $45.00 to $67.00 in a research report on Friday, December 13th. Three analysts have rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $62.08.

PTC Therapeutics Stock Up 0.3 %

Shares of PTC Therapeutics stock opened at $51.93 on Thursday. The firm has a market cap of $4.01 billion, a price-to-earnings ratio of -8.74 and a beta of 0.62. The business has a fifty day simple moving average of $47.57 and a 200-day simple moving average of $42.65. PTC Therapeutics has a fifty-two week low of $24.00 and a fifty-two week high of $55.60.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PTCT. Smartleaf Asset Management LLC raised its stake in shares of PTC Therapeutics by 78.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 270 shares in the last quarter. Sterling Capital Management LLC increased its stake in shares of PTC Therapeutics by 424.4% in the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 522 shares during the period. Venturi Wealth Management LLC bought a new position in shares of PTC Therapeutics in the fourth quarter worth about $68,000. GF Fund Management CO. LTD. bought a new position in shares of PTC Therapeutics in the fourth quarter worth about $73,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of PTC Therapeutics in the fourth quarter worth about $77,000.

Insider Buying and Selling

In related news, CAO Christine Marie Utter sold 879 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $44,037.90. Following the transaction, the chief accounting officer now directly owns 63,442 shares of the company’s stock, valued at approximately $3,178,444.20. This trade represents a 1.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Mark Elliott Boulding sold 1,543 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total value of $69,959.62. Following the completion of the transaction, the vice president now directly owns 108,846 shares in the company, valued at $4,935,077.64. The trade was a 1.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,640 shares of company stock worth $1,012,288. Insiders own 5.50% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.